PTPN11 and neoplasm: Additionally, the combined targeting of KRASG12C with cell cycle checkpoints or immune checkpoints is promising [50,72,117]; the triple combined inhibition of KRASG12C/SHP2/PD-L1 leads to severe tumor regression in PDAC mouse models [108].